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ABSTRACT: Identification and management of patients at high bleeding 
risk undergoing percutaneous coronary intervention are of major 
importance, but a lack of standardization in defining this population 
limits trial design, data interpretation, and clinical decision-making. 
The Academic Research Consortium for High Bleeding Risk (ARC-HBR) 
is a collaboration among leading research organizations, regulatory 
authorities, and physician-scientists from the United States, Asia, and 
Europe focusing on percutaneous coronary intervention–related bleeding. 
Two meetings of the 31-member consortium were held in Washington, 
DC, in April 2018 and in Paris, France, in October 2018. These meetings 
were organized by the Cardiovascular European Research Center on 
behalf of the ARC-HBR group and included representatives of the US 
Food and Drug Administration and the Japanese Pharmaceuticals and 
Medical Devices Agency, as well as observers from the pharmaceutical 
and medical device industries. A consensus definition of patients at high 
bleeding risk was developed that was based on review of the available 
evidence. The definition is intended to provide consistency in defining this 
population for clinical trials and to complement clinical decision-making 
and regulatory review. The proposed ARC-HBR consensus document 
represents the first pragmatic approach to a consistent definition of 
high bleeding risk in clinical trials evaluating the safety and effectiveness 
of devices and drug regimens for patients undergoing percutaneous 
coronary intervention.
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The evolution of percutaneous coronary interven-tion (PCI) over the last 40 years has facilitated treatment of increasingly complex patient popu-
lations. One such population comprises patients at high 
bleeding risk (HBR). In early trials of first-generation 
drug-eluting stents (DES), the protocol-recommended 
dual antiplatelet therapy (DAPT) duration was 3 to 6 
months, but as a result of concerns about late throm-
botic events, this was increased to 12 months in studies 
initiated after 2006.1 Coinciding with this shift, patients 
considered to be at HBR were either excluded from or 
underrepresented in clinical trials. The accepted prac-
tice in such patients was bare metal stent (BMS) im-
plantation, given that 1 month of DAPT was considered 
sufficient at that time. Until recently, even more inclu-
sive studies of contemporary DES continued to exclude 
patients for whom guideline-recommended DAPT was 
considered unsuitable.2,3
Recently, 3 randomized trials comparing DES and 
BMS with 1 month of DAPT in patients perceived to be 
at increased bleeding risk showed superior safety and 
efficacy with DES.4–6 These reports quickly generated 
global attention as an important public health concern 
given that, as recently as 2014, BMSs were used in 
20% of coronary stenting procedures in patients ≥65 
years of age in the United States, with 18.2% of BMS 
recipients having a predicted bleeding risk of ≥5%/y.7
The challenges in defining the optimal management 
of patients undergoing PCI at HBR include a paucity 
of relevant clinical data and the use of heterogeneous 
definitions of HBR that limit interpretation, generaliza-
tion, and pooling of published data. In 2006, the first 
Academic Research Consortium (ARC) provided stan-
dardized definitions of ischemic end points for coro-
nary stent trials, and in 2011, the Bleeding ARC (BARC) 
provided bleeding end point definitions, both of which 
have gained wide acceptance in clinical study design, 
demonstrating the value of consensus-based defini-
tions in the PCI field.8,9
With this in mind, the aim of the ARC-HBR initiative is 
to define HBR in patients undergoing PCI on the basis of 
a literature review and clinical consensus with the prima-
ry goal of advancing the consistency and quality of data 
collection and reporting, thereby supporting organiza-
tions tasked with making recommendations for clinical 
practice or regulatory decisions.10 To this end, 2 meet-
ings of the ARC-HBR group were organized by the Car-
diovascular European Research Center (Massy, France) 
in Washington, DC, in April 2018 and Paris, France, in 
October 2018. International academic experts; repre-
sentatives of the US Food and Drug Administration, the 
Japanese Pharmaceuticals and Medical Devices Agency, 
and a European Notified Body (DEKRA, Arnhem, the 
Netherlands); and observers from the device and phar-
maceutical industries attended (participants are listed in 
the Appendix in the online-only Data Supplement).
CONTEMPORARY CLINICAL TRIALS 
OF CORONARY STENTS AND 
ANTIPLATELET THERAPY: NOT 
GENERALIZABLE TO PATIENTS AT HBR
Regulatory approval processes for medical devices differ 
between jurisdictions.11 In the United States, for exam-
ple, completed pivotal randomized trials of investiga-
tional DES submitted for US Food and Drug Administra-
tion review have been prospective, multicenter studies 
with high internal validity, but enrollment has been lim-
ited to highly selected patients and lesions.12–18 Patients 
considered unsuitable for protocol-mandated DAPT 
duration have been excluded. Although more recent 
DES trials have had more liberal enrollment criteria, per 
protocol or de facto, they have continued to exclude 
patients with advanced renal impairment, prior bleed-
ing, prior recent stroke, and hematologic abnormalities 
(Table I in the online-only Data Supplement).16–18
Many investigator-initiated “all-comer” random-
ized trials included some patients at increased bleeding 
risk.2,19–24 However, only a minority of screened patients 
tend to be enrolled, mean patient age is similar to that 
Abbreviations
ACS acute coronary syndrome
AF atrial fibrillation
ARC Academic Research Consortium
BARC Bleeding Academic Research Consortium
bAVM brain arteriovenous malformation
BMS bare metal stent
CAD coronary artery disease
CKD chronic kidney disease
DAPT dual antiplatelet therapy
DES drug-eluting stent
eGFR estimated glomerular filtration rate
HBR high bleeding risk
HR hazard ratio
ICH intracranial hemorrhage
NIS Nationwide Inpatient Sample
NSAID nonsteroidal anti-inflammatory drug
OAC oral anticoagulant
OR odds ratio
PCI percutaneous coronary intervention
TIA transient ischemic attack
VKA vitamin K antagonist
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in earlier trials, patients unsuitable for long-term DAPT 
continue to be systematically excluded, and details on 
the proportion of patients taking oral anticoagulation 
(OAC) or with other bleeding risk factors are not con-
sistently reported.2,19–24 Thus, despite broader inclusion 
criteria, subjects at HBR are still underrepresented in 
contemporary studies.
Clinical trials of DAPT strategies after stenting have 
also excluded patients at HBR, with reported major 
bleeding rates at 1 year varying between 0.3% and 
2.8% (Table 1).25–34
CONTEMPORARY CLINICAL TRIALS 
IN PATIENTS AT INCREASED RISK OF 
BLEEDING
Three randomized trials investigating short DAPT du-
rations have been completed in patients undergoing 
PCI perceived to be at increased bleeding risk,4–6 and 
many trials are currently ongoing (Table II in the online-
only Data Supplement). Inclusion criteria in these trials 
largely reflect exclusion criteria in prior DES studies of 
patients not at HBR receiving different DAPT durations, 
but there is significant heterogeneity with respect to 
the patient populations included.
Among completed studies, the LEADERS FREE trial 
(Polymer-free drug-coated coronary stents in patients at 
high bleeding risk; n=2466) was the trial most broadly 
inclusive of patients at HBR to date, with a mean of 
1.7 bleeding risk criteria per patient.4 The ZEUS trial 
(Zotarolimus-Eluting Endeavor Sprint Stent in Uncertain 
DES Candidates; n=1606) enrolled uncertain DES candi-
dates on the basis of criteria for high thrombotic, reste-
notic, or bleeding risk,35 with a prespecified subgroup 
analysis of patients who met criteria for HBR (ZEUS-HBR; 
n=828).5 The SENIOR trial (Drug-eluting stents in elder-
ly patients with coronary artery disease: a randomised 
single-blind trial; n=1200) included elderly patients with 
no other specified inclusion criteria associated with in-
creased bleeding risk.6 The most frequently met criterion 
associated with increased bleeding risk in all 3 trials was 
advanced age (in 64%, 51%, and 100% of patients in 
LEADERS FREE, ZEUS-HBR, and SENIOR, respectively), 
although the lower cutoff for age differed between tri-
als (>80 years in ZEUS-HBR versus ≥75 years in LEAD-
ERS FREE and SENIOR). The second most frequently met 
characteristic was indication for OAC in 36%, 38%, 
Table 1. One-Year Bleeding Rates in Trials of Antiplatelet Therapy After Coronary Stenting
Trial (Year of Publication) Patients, n Type of Patients
Inclusion of 
Periprocedural 
Bleeding
Overall 
Bleeding, %
Bleeding Definition 
Used
Adjudication of 
Bleeding Events
RESET (2012)25 2117 Selected low 
bleeding risk
Yes 0.7 TIMI major or minor CEC adjudicated
EXCELLENT (2012)26 1443 Selected low 
bleeding risk
Yes 1 TIMI major or minor CEC adjudicated
ARCTIC (2012)27 2440 All comers Yes 2.8 STEEPLE major CEC adjudicated
PRODIGY (2012)28 1970 All comers No (first 30 d 
excluded)
2.0† BARC 3 or 5 CEC adjudicated
OPTIMIZE (2013)29 3119 Selected low 
bleeding risk
Yes 0.5 Protocol-defined CEC adjudicated
DAPT* (2014)30 22 866 Selected low 
bleeding risk
Yes 2.7 GUSTO moderate or 
severe
CEC adjudicated
SECURITY (2014)31 1399 Selected low 
bleeding risk
Yes 0.9 BARC 3 or 5 CEC adjudicated
PRECISE-DAPT (2017)32 14 963 Selected low 
bleeding risk
No (first 7 d 
excluded)
1.5 TIMI major or minor CEC adjudicated
SMART-DATE (2018)34 2712 ACS Yes 0.3† BARC 3 or 5 CEC adjudicated
GLOBAL LEADERS (2018)33 15 968 All comers Yes 1.9† BARC 3 or 5 Site reported
Bleeding definitions are shown in the Appendix in the online-only Data Supplement. 
ACS indicates acute coronary syndrome; ARCTIC, bedside monitoring to adjust antiplatelet therapy for coronary stenting; BARC, Bleeding Academic Research 
Consortium; CEC, Clinical Events Committee; DAPT, Dual Antiplatelet Therapy Trial; EXCELLENT, Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss 
After Stenting; GLOBAL LEADERS, Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor 
for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial; 
GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries; OPTIMIZE, Optimized Duration of Clopidogrel Therapy 
Following Treatment With the Endeavor; PRECISE-DAPT, Predicting Bleeding Complications In Patients Undergoing Stent Implantation and Subsequent Dual Anti 
Platelet Therapy; PRODIGY, Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study; RESET, Real Safety and Efficacy of 
3-Month Dual Antiplatelet Therapy Following Endeavor Zotarolimus-Eluting Stent Implantation; SECURITY, Second Generation Drug-Eluting Stents Implantation 
Followed by Six Versus Twelve-Month Dual-Antiplatelet Therapy; SMART-DATE, Safety of 6-Month Duration of Dual Antiplatelet Therapy After Acute Coronary 
Syndromes; STEEPLE, Safety and Efficacy of Enoxaparin in PCI Patients, an International Randomized Evaluation; and TIMI, Thrombolysis in Myocardial Infarction.
*First year after enrollment, before randomization.
†One-year bleeding rates were obtained as personal communications from the principal investigators of these 3 trials.
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and 18% of patients, respectively. Although renal im-
pairment was the third most commonly met criterion in 
LEADERS FREE (19%), it was not a prespecified criterion 
for HBR status in ZEUS-HBR. Early planned surgery was 
a bleeding risk inclusion criterion in LEADERS FREE (met 
in 16% of patients), but such patients were excluded 
in ZEUS-HBR and SENIOR. Prior hemorrhagic stroke was 
also an inclusion criterion in LEADERS FREE but was an 
exclusion criterion in SENIOR, and although it was not 
an exclusion criterion in ZEUS-HBR, no information on 
its prevalence is provided. Bleeding rates according to 
inclusion criteria in LEADERS FREE are shown in Table III 
in the online-only Data Supplement.
The differences in eligibility criteria and enrolled pa-
tient populations in completed trials are reflected in the 
differences in bleeding event rates. In LEADERS FREE 
and ZEUS-HBR, the 1-year rates of BARC 3 to 5 bleeding 
in patients treated with 1-month DAPT after PCI were 
7.3% and 4.2%, respectively, and in the SENIOR trial, 
the 1-year BARC 3 to 5 bleeding rate in patients treated 
with 1 to 6 months of DAPT after PCI was ≈3.5%. Such 
differences highlight the need for a standardized defini-
tion of HBR.
CURRENTLY AVAILABLE BLEEDING 
RISK SCORES
At least 6 scores have been developed that predict 
long-term bleeding risk in patients taking antiplatelet 
therapy.32,36–39 The 2017 European Society of  Cardiology 
Table 2. Scores Assessing Long-Term Bleeding Risk in Patients Taking Antiplatelet Therapy
REACH39 Dutch ASA Score37 DAPT41* PARIS38 PRECISE-DAPT32 BleeMACS36
Year of publication 2010 2014 2016 2016 2017 2018
Development data 
set
REACH registry Dutch ASA registry DAPT randomized 
trial
PARIS registry Pooled analysis of 8 
randomized trials
BleeMACS registry
Development data 
set, n
56 616 235 531 11 648 4190 14 963 15 401
Patient population Risk of 
atherothrombosis†
New low-dose 
aspirin users
Stable and event-
free patients 12 mo 
after PCI
Stable and unstable 
patients undergoing 
PCI
Stable and unstable 
patients undergoing 
PCI
Patients with ACS 
undergoing PCI
Bleeding outcome Serious bleeding
at 2 y
Upper GI bleeding at 
a median follow-up 
of 530 d
Major bleeding 
between 12 and 30 
mo after PCI
Major bleeding
at 2 y
Out-of-hospital 
bleeding at a median 
follow-up of 552 d
Serious spontaneous 
bleeding at 1 y
Bleeding definition 
used
Protocol-defined First episode of 
upper GI bleeding
GUSTO moderate or 
severe
BARC 3 or 5 TIMI major or minor Protocol-defined
Proportion of 
patients at HBR
25% (score >11) 83.1% (score ≥1) 23.4% (score −2 
to 0)
8% (score ≥8) 25% (score ≥25) 25% (score ≥26)
Rate of bleeding in 
the HBR subgroup
2.76%
(at 2 y)
1%–35% for scores 
from 2 to 13
2.7%
(between 13 and 
30 mo)
10.7%
(at 2 y)
1.8%–4.2%
(at 1 y)
8.03%
(at 1 y)
Also evaluates 
thrombotic risk
No No Yes Yes No No
Score range 0 to 23 0 to 15 –2 to 10 0 to 14 0 to 100 0 to 80
Development 
discrimination
AUC 0.68 AUC 0.64 AUC 0.68 AUC 0.72 AUC 0.73 AUC 0.71 (0.72 in 
internal validation)
Validating data set CHARISMA Dutch health 
insurance database
PROTECT ADAPT-DES PLATO and
Bern PCI registry
SWEDEHEART
Validating dataset, 
n
15 603 32 613 8136 8130 8595 and
6172
96 239 (ACS+PCI);
93,150 (ACS)
Validation 
discrimination
AUC 0.64 AUC 0.63 AUC 0.64 (bleeding) AUC 0.64 AUC 0.70 and 0.66 AUC 0.65 
(ACS+PCI);
AUC 0.63 (ACS)
Bleeding definitions are shown in the Appendix in the online-only Data Supplement. 
ACS indicates acute coronary syndrome; ADAPT-DES, Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents; ASA, aspirin; AUC, area under the 
curve; BARC, Bleeding Academic Research Consortium; BleeMACS, Bleeding Complications in a Multicenter Registry of Patients Discharged With Diagnosis of Acute 
Coronary Syndrome; CHARISMA, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance; DAPT, Dual Antiplatelet 
Therapy Trial; GI, gastrointestinal; GUSTO, Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries; HBR, high bleeding risk; PARIS, patterns of 
non-adherence to anti-platelet regimens in stented patients; PCI, percutaneous coronary intervention; PLATO, Platelet Inhibition and Patient Outcomes; PRECISE-
DAPT, Predicting Bleeding Complications In Patients Undergoing Stent Implantation and Subsequent Dual Anti Platelet Therapy; PROTECT, Patient Related Outcomes 
With Endeavor Versus Cypher Stenting Trial; REACH, Reduction of Atherothrombosis for Continued Health Registry; and TIMI, Thrombolysis in Myocardial Infarction.
*The DAPT score is not purely a bleeding risk score; rather, it is a score to predict benefit versus harm of prolonged dual antiplatelet therapy (>1 year) in patients 
after percutaneous coronary intervention. Thus, it integrates covariates independently associated with bleeding (but not ischemic) risk and vice versa.
†Risk of atherothrombosis in REACH was defined as cardiovascular disease, coronary artery disease, peripheral artery disease, or ≥3 cardiovascular risk factors.
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focused update on DAPT in coronary artery disease 
(CAD) recommended (Class IIb recommendation, Lev-
el of Evidence A) that the use of risk scores such as 
the PRECISE-DAPT (Predicting Bleeding Complications 
In Patients Undergoing Stent Implantation and Subse-
quent Dual Anti Platelet Therapy) and DAPT scores may 
be considered to guide antiplatelet therapy after PCI.40
The main features of existing scores are summarized in 
Table 2, and the variables in each score are shown in Table 
IV in the online-only Data Supplement.32,36–39,41 Advanced 
age is the only variable common to all scores, but age cut-
offs for increased bleeding risk and their relative weights 
vary between risk scores. In addition, although baseline 
anemia was found to be one of the strongest indepen-
dent predictors of bleeding assessed in PARIS (patterns 
of non-adherence to anti-platelet regimens in stented 
patients), BleeMACS (Bleeding Complications in an Mul-
ticenter Registry of Patients Discharged With Diagnosis of 
Acute Coronary Syndrome), the Dutch aspirin score, and 
PRECISE-DAPT,32,36–38 it was not assessed in the develop-
ment of the REACH (Reduction of Atherothrombosis for 
Continued Health Registry) or DAPT score.39,41 Moreover, 
definitions of anemia differed between studies.
Five variables (prior malignancy, congestive heart 
failure, body mass index <25 or ≥35 kg/m2, hypercho-
lesterolemia, and elevated white cell count) are pres-
ent in only 1 score. Furthermore, all scores omit certain 
important variables known to be associated with HBR 
because their prevalence is low in patients with CAD or 
those undergoing PCI (eg, severe liver disease, bleeding 
diatheses, or thrombocytopenia), because they were 
rarely recorded in the derivation data sets (eg, history 
of cancer or prior bleeding, use of nonsteroidal anti-
inflammatory drugs [NSAIDs], or planned surgery), or 
because collinearity with other selected predictors may 
have overshadowed their significance.
Such differences in risk prediction scores reflect het-
erogeneity in the patient populations studied, the vari-
ables assessed (and their definitions), and the bleeding 
definitions used in the development cohorts. At best, 
these scores have moderate accuracy for predicting 
bleeding, with C statistics in the development cohorts 
ranging from 0.64 to 0.73 (Table 2). Moreover, none of 
these scores was validated in HBR patient populations, 
highlighting the need for standardized HBR criteria for 
evaluating such patients.
DEFINING HBR CRITERIA
HBR is defined as a BARC 3 or 5 bleeding risk of ≥4% 
at 1 year or a risk of an intracranial hemorrhage (ICH) 
of ≥1% at 1 year. Thus, a major criterion for ARC-HBR is 
defined as any criterion that, in isolation, is considered 
to confer a BARC 3 or 5 bleeding risk of ≥4% at 1 year 
or any criterion considered to be associated with a risk 
of ICH of ≥1% at 1 year. A minor criterion for ARC-HBR 
is defined as any criterion that, in isolation, is consid-
ered to confer increased bleeding risk, with a BARC 3 
or 5 bleeding rate of <4% at 1 year.
The cutoff value of 4% for BARC 3 or 5 bleeding was 
based on consensus of the participants, taking into ac-
count that 1-year major bleeding rates in trials of DAPT 
after PCI, which largely excluded patients at HBR, were 
<3% (Table 1) and that, in DES trials enrolling patients 
at HBR, 1-year BARC 3 to 5 bleeding rates were higher 
(7.2% in LEADERS FREE [with 1.7 HBR criteria per pa-
tient] and 4.2% in ZEUS-HBR despite only 1 month of 
DAPT after PCI) and 3.5% in the SENIOR trial (in which 
age ≥75 years was the sole inclusion criterion).
PROPOSED HBR DEFINITION
Twenty clinical criteria were identified as major or minor 
by consensus, supported by published evidence (Table 3 
and Figure). Patients are considered to be at HBR if at 
least 1 major or 2 minor criteria are met. The definition 
is thus binary. Although it is recognized that the coexis-
tence of increasing numbers of risk factors for bleeding is 
associated with a stepwise increase in risk of BARC 3 to 
5 bleeding,5 sufficient data are not currently available to 
create a point-based score that would take into account 
the relative weight of each HBR criterion. Nonetheless, 
the presence of increasing numbers of major or minor cri-
teria in any patient further increases bleeding risk, which 
may be considered in clinical decision-making and clini-
cal trial analysis. The proposed consensus-based defini-
tion takes into account the available evidence for patients 
at HBR undergoing PCI and is pragmatic for application 
to clinical trials supporting clinical practice recommenda-
tions and regulatory review. The criteria making up the 
definition are discussed below. Associated major (prefer-
ably BARC 3 or 5) bleeding rates or rates of ICH at 1 year 
are provided when available. Factors that were consid-
ered but not deemed HBR criteria are also discussed.
Age
Age ≥75 years is considered a minor ARC-HBR criterion 
(Table 3).
Although elderly patients represent the fastest-grow-
ing patient subgroup undergoing PCI,43,44 they tend to 
be underrepresented in randomized trials of DES and 
DAPT. In the SENIOR trial, which included patients ≥75 
years of age (mean age, 81.4±4.2 years) treated with 1 
or 6 months of DAPT after coronary stenting (DES ver-
sus BMS), the 1-year rate of BARC 3 to 5 bleeding was 
≈3.5%. Indeed, elderly patients undergoing PCI tend 
to have more comorbidities and coexisting risk fac-
tors for bleeding compared with younger patients.45 A 
substudy of elderly patients (≥75 years) enrolled in the 
LEADERS FREE trial (n=1564) showed that patients who 
qualified for inclusion on the basis of age alone (n=562) 
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had a lower rate of 1-year BARC 3 to 5 bleeding com-
pared with the overall elderly population (3.2% versus 
7.8%, respectively).46 Nonetheless, in the development 
cohorts of bleeding risk scores in patients undergoing 
PCI, advanced age generally persisted as an indepen-
dent predictor of bleeding after adjustment for coexist-
ing bleeding risk factors.32,38,41,47–51
In a patient-level meta-analysis of 6 randomized tri-
als (n=11 473) comparing short (≤6 months) and longer 
(12 months) DAPT duration after PCI, short DAPT halved 
the rate of protocol-defined major bleeding at 1 year in 
patients ≥65 years of age (0.5% versus 1.1%; hazard 
ratio [HR], 0.46 [95% CI, 0.24–0.88]; P=0.02), without 
increasing ischemic events (2.4% versus 3.0%; HR, 0.84 
[95% CI, 0.60–1.16]; P=0.2856). In contrast, in younger 
patients, short DAPT failed to reduce bleeding (0.3% 
versus 0.5%; HR, 0.59 [95% CI, 0.26–1.34]; P=0.21), 
but ischemic events were significantly increased (2.4% 
versus 1.4%; HR, 1.67 [95% CI, 1.14–2.44]; P=0.0082), 
suggesting differential bleeding–ischemic risk profiles in 
elderly versus younger patients after PCI.52
In summary, bleeding risk increases with age with 
some confounding resulting from comorbidities, which 
tend to accumulate in elderly patients. With this in 
mind, it must be acknowledged that biological age and 
chronological age may differ. Although the relationship 
between age and bleeding risk appears to be continu-
ous, a pragmatic decision was made to use a binary 
variable in the current definition.
Oral Anticoagulation
The anticipated use of long-term OAC (with a vitamin 
K antagonist [VKA] or non–vitamin K OAC) after PCI is 
considered a major ARC-HBR criterion (Table 3).
The most common indication for OAC in patients 
undergoing PCI is coexisting atrial fibrillation (AF). 
When treating such patients, physicians must balance 
the risk of thromboembolism with AF, the risk of stent 
thrombosis and myocardial infarction after PCI, and the 
risk of bleeding on combined antithrombotic therapy.53 
Bleeding risk is magnified in the setting of triple anti-
thrombotic therapy (OAC plus DAPT).54
In the WOEST trial (What Is the Optimal antiplatelet 
and Anticoagulant Therapy in Patients With Oral An-
ticoagulation and Coronary Stenting; n=573), 1-year 
rates of BARC 3 to 5 bleeding in patients on VKAs 
after PCI were 6.5% and 12.7% in the double (VKA 
plus clopidogrel) and triple (VKA plus aspirin and clopi-
dogrel) therapy arms, respectively (HR, 0.49 [95% CI, 
0.28–0.86]; P=0.011).55 In the ISAR-TRIPLE trial (Intra-
coronary Stenting and Antithrombotic Regimen-Testing 
of a 6-Week versus a 6-Month Clopidogrel Treatment 
Regimen in Patients with Concomitant Aspirin and Oral 
Anticoagulant Therapy Following Drug-Eluting Stenting; 
n=614), patients on a VKA undergoing PCI were ran-
domized to treatment with triple therapy for 6 weeks 
versus 6 months, with continuation of VKA and aspirin 
thereafter.56 At 9 months, rates of BARC 3 to 5 bleed-
ing were ≈11.1% and 10.4%, respectively, with compa-
rable bleeding event rates between treatment groups.
In the PIONEER AF-PCI trial (Open-Label, Random-
ized, Controlled, Multicenter Study Exploring Two 
Treatment Strategies of Rivaroxaban and a Dose-Ad-
justed Oral Vitamin K Antagonist Treatment Strategy 
in Subjects With Atrial Fibrillation Who Undergo Percu-
taneous Coronary Intervention) and RE-DUAL PCI trial 
(Evaluation of Dual Therapy With Dabigatran vs. Triple 
Therapy With Warfarin in Patients With AF That Under-
go a PCI With Stenting), patients with AF undergoing 
PCI were allocated to treatment with dual therapy con-
sisting of a non–vitamin K OAC and a P2Y12  inhibitor or 
Table 3. Major and Minor Criteria for HBR at the Time of PCI
Major Minor
 Age ≥75 y
Anticipated use of long-term oral 
anticoagulation*
 
Severe or end-stage CKD (eGFR <30 
mL/min)
Moderate CKD (eGFR 30–59 mL/
min)
Hemoglobin <11 g/dL Hemoglobin 11–12.9 g/dL for men 
and 11–11.9 g/dL for women
Spontaneous bleeding requiring 
hospitalization or transfusion in the 
past 6 mo or at any time, if recurrent
Spontaneous bleeding requiring 
hospitalization or transfusion 
within the past 12 mo not 
meeting the major criterion
Moderate or severe baseline 
thrombocytopenia† (platelet count 
<100×109/L)
 
Chronic bleeding diathesis  
Liver cirrhosis with portal 
hypertension
 
 Long-term use of oral NSAIDs or 
steroids
Active malignancy‡ (excluding 
nonmelanoma skin cancer) within the 
past 12 mo
 
Previous spontaneous ICH (at any 
time)
Previous traumatic ICH within the 
past 12 mo
Presence of a bAVM
Moderate or severe ischemic stroke§ 
within the past 6 mo
Any ischemic stroke at any time 
not meeting the major criterion
Nondeferrable major surgery on DAPT  
Recent major surgery or major trauma 
within 30 d before PCI
 
bAVM indicates brain arteriovenous malformation; CKD, chronic kidney 
disease; DAPT, dual antiplatelet therapy; eGFR, estimated glomerular filtration 
rate; HBR, high bleeding risk; ICH, intracranial hemorrhage; NSAID, nonsteroidal 
anti-inflammatory drug; and PCI, percutaneous coronary intervention.
*This excludes vascular protection doses.42
†Baseline thrombocytopenia is defined as thrombocytopenia before PCI.
‡Active malignancy is defined as diagnosis within 12 months and/or ongoing 
requirement for treatment (including surgery, chemotherapy, or radiotherapy).
§National Institutes of Health Stroke Scale score ≥5.
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triple therapy consisting of a VKA, a P2Y12 inhibitor, and 
aspirin. Although bleeding rates were lower in patients 
on dual therapy, it is unclear to what extent this was at-
tributable to the omission of aspirin as opposed to the 
use of a non–vitamin K OAC instead of a VKA.57,58 In 
PIONEER AF-PCI (n=2124), 1-year BARC 3 to 5 bleeding 
rates were 4.1% with dual therapy including low-dose 
rivaroxaban (15 mg daily), 4.4% with triple therapy in-
cluding very-low-dose rivaroxaban (2.5 mg twice daily), 
and 7.9% with triple therapy including a VKA. In RE-
DUAL PCI (n=2725), respective rates of TIMI (Thrombol-
ysis in Myocardial Infarction) major/minor bleeding at 
14 months were 3.0% versus 7.0% in patients treated 
with dual therapy with dabigatran 110 mg twice daily 
versus triple therapy with warfarin (HR, 0.41 [95% CI, 
0.26–0.63]; P<0.001) and 3.5% versus 6.3% in those 
treated with dual therapy including dabigatran 150 
mg twice daily versus triple therapy including warfarin 
(HR, 0.53 [95% CI, 0.33–0.85]; P=0.009). In both trials, 
bleeding rates in the groups treated with triple therapy 
with a VKA were markedly lower than those observed 
in WOEST and ISAR-TRIPLE, indicating an overall lower 
bleeding risk profile in the populations enrolled, possi-
bly explained by the stricter patient selection criteria in 
PIONEER AF-PCI and RE-DUAL PCI.
Although bleeding risk may differ between VKAs 
and novel anticoagulants and between individual novel 
anticoagulants (Table V in the online-only Data Supple-
ment) and different doses, exposure times and varia-
tions in renal function may confer differential bleeding 
risks. Weighting the relative bleeding risk with different 
OAC regimens is beyond the scope of this definition.
Chronic Kidney Disease
Severe or end-stage chronic kidney disease (CKD; esti-
mated glomerular filtration rate [eGFR] <30 mL/min) is 
considered a major ARC-HBR criterion, and moderate 
CKD (eGFR, 30–59 mL/min) is considered a minor ARC-
HBR criterion (Table 3).
Approximately 30% of patients undergoing PCI 
have an eGFR <60 mL/min,59 but patients with severe 
CKD have generally been excluded from randomized 
trials. Even mild CKD is an independent risk factor for 
bleeding after PCI,60,61 and the risk increases incremen-
tally with worsening CKD (Table  4).60–64 One mecha-
nism may be reduced clearance of certain antithrom-
botic medications. In the PRECISE-DAPT bleeding risk 
score,32 eGFR <30 mL/min in isolation places patients 
in the highest quartile for bleeding risk, whereas mild-
er CKD is associated with a slightly to moderately in-
creased bleeding risk.
The increased bleeding risk with CKD must be con-
sidered in the context of a proportionately increased 
risk of ischemic events (Table 4), making this balance 
more sensitive in patients with CKD compared with 
most other HBR criteria. In the DAPT score, a clinical 
decision tool to identify patients expected to derive 
benefit versus harm from prolonged DAPT after PCI, 
CKD is not a variable because the associated bleed-
ing risk was balanced by an almost identical ischemic 
risk.41
From the data presented, the consensus decision 
was to use CKD stages rather than eGFR as a continu-
ous variable in the definition (Table 4).
Figure. Factors associated with an increased bleeding risk after percutaneous coronary intervention. 
bAVM indicates brain arteriovenous malformation; CNS, central nervous system; DAPT, dual antiplatelet treatment; ICH, intracranial hemorrhage; NSAID, nonste-
roidal anti-inflammatory drug; and OAC, oral anticoagulation.
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Anemia
A hemoglobin level <11 g/dL is considered a major 
ARC-HBR criterion. A hemoglobin level of 11 to 12.9 g/
dL for men and 11 to 11.9 g/dL for women is consid-
ered a minor ARC-HBR criterion (Table 3).
Anemia defined by World Health Organization cri-
teria (hemoglobin <13 g/dL in men and <12 g/dL in 
women) is frequently encountered in patients undergo-
ing PCI, with a reported prevalence of 21.6% in the 
Bern DES Registry.65 Anemia correlates with the risk of 
future bleeding in patients undergoing PCI. The 1-year 
risk of BARC 3 or 5 bleeding in patients with acute 
coronary syndrome (ACS) treated with PCI followed by 
prasugrel or ticagrelor in the RENAMI registry (Registry 
of New Antiplatelets in Patients With Myocardial Infarc-
tion; n=4424) was significantly higher in patients with 
World Health Organization–defined anemia compared 
with those without (5.4% versus 1.5%, respectively; 
P=0.001).66 In a meta-analysis of 44 studies including 
>230 000 patients undergoing PCI, anemia (defined by 
World Health Organization criteria in the majority of 
studies) was present in 16% of patients and was as-
sociated with a 2-fold risk of subsequent bleeding (as 
defined in individual studies; adjusted risk ratio, 2.31 
[95% CI, 1.44–3.71]), as well as an increased risk of 
ischemic events and mortality.67 Furthermore, bleeding 
risk increased with increasing severity of anemia.
Baseline anemia was also found to be an important 
predictor of bleeding in the development cohorts of a 
number of bleeding risk scores. In PARIS, baseline anemia 
(hemoglobin <12 g/dL in men and <11 g/dL in women) 
was a strong predictor of 2-year BARC 3 or 5 bleeding 
(9.5% with versus 2.7% without anemia; adjusted HR, 
2.72 [95% CI, 1.83–4.04]; P<0.0001).38 In BleeMACS, 
hemoglobin <11 g/dL was the strongest predictor of 
serious spontaneous bleeding (defined in the Appendix 
in the online-only Data Supplement) at 1 year (adjusted 
HR, 2.41 [95% CI, 1.29–4.50]; P<0.001), and hemo-
globin of 11.0 to 13.9 g/dL was also  associated with a 
Table 4. Impact of CKD on Clinical Outcomes After PCI
CrCl, mL/min
Major Bleeding Ischemic Events
End Point(s) 
and Duration of 
Follow-Up Event Rate, % P Value
End Point(s) and 
Duration of Follow-
Up Event Rate, % P Value
EVENT registry62
(n=4791)
>75  
(n=2827, (59%)
In-hospital 
TIMI major or 
minor bleeding, 
major vascular 
complications, or 
transfusion/TIMI 
major bleeding
3.3/0.2 <0.0001/
0.56
MI in hospital/at 1 y 5.7/7.2 <0.001/
0.0007
50–75  
(n=1253, 26%)
5.0/0.3 7.3/9.2
30–49  
(n=571, 12%)
8.8/1.2 8.2/10.7
<30  
(n=140, 3%
14.3/0.0 10.0/11.4
ACUITY trial60
(n=13 819)
≥60  
(n=11 350, 80.9)
ACUITY major 
bleeding at 30 d
3.6 <0.0001 Death resulting 
from any cause, 
MI, or unplanned 
revascularization at 
ischemia) 30 d/1 y
7.0/14.4 <0.0001/
0.001
<60  
(n=2469, 19.1%)
9.2 10.8/21.6
HORIZON-AMI trial61
(n=3397)
≥60  
(n=2843, 83.7%)
ACUITY major 
bleeding at 30 d/1 
y/2 y
5.7/6.0/6.7 <0.0001/
<0.0001/
<0.0001
Death, reinfarction, 
TVR, or stroke at 30 
d/1 y/2 y
4.3/10.1/19.8 <0.0001/
<0.0001/
<0.0001
30–60  
(n=506, 14.9%)
12.1/14.3/16.9 9.9/18.5/30.0
≤30  
(n=48, 1.4%)
45.2/45.2/45.2 29.2/49.3/70.0
PARIS Registry63
(n=4584)
≥60  
(n=3745, 82.0%)
BARC 3 or 5 
bleeding at 2 y
3.04 NR Cardiac death, 
probable/definite ST, 
or clinically indicated 
TVR at 2 y
10.20 NR
<60  
(n=839, 18.0%)
8.94 16.81
ADAPT-DES64
(n=8410)
≥60  
(n=7043, 83.7%)
ACUITY major 
bleeding at 2 y
7.5 <0.001 Cardiac death, MI, or 
ischemia-driven TLR 
at 2 y
9.9 <0.001
<60  
(n=1367 (16.3%)
13.9 15.3
Bleeding definitions are shown in the Appendix in the online-only Data Supplement. ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; 
ADAPT-DES, Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents; BARC, Bleeding Academic Research Consortium; CKD, chronic kidney disease; CrCl, 
creatinine clearance; EVENT, Evaluation of Drug Eluting Stents and Ischemic Events; HORIZON-AMI, Harmonizing Outcomes With Revascularization and Stents in Acute 
Myocardial Infarction; MI, myocardial infarction; NR, not reported; PARIS, patterns of non-adherence to anti-platelet regimens in stented patients; PCI, percutaneous 
coronary intervention; ST, stent thrombosis; TIMI, Thrombolysis in Myocardial Infarction; TLR, target lesion revascularization; and TVR, target vessel revascularization.
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significantly increased bleeding risk (adjusted HR, 1.59 
[95% CI, 1.14–2.21]; P=0.006) compared with hemo-
globin ≥14 g/dL.36 In the Dutch aspirin score, anemia 
(defined by diagnosis-related groups) was also found to 
be one of the most important predictors of a first up-
per gastrointestinal bleed on aspirin therapy (adjusted 
HR, 2.3 [95% CI, 1.9–2.8]; P<0.01).37 In PRECISE-DAPT, 
each 1-g/dL increase in hemoglobin between 10 and 
12 g/dL was independently associated with a reduction 
in the risk of TIMI major/minor bleeding at 1 year (ad-
justed HR, 0.67 [95% CI, 0.53–0.84]; P=0.001).32
Prior Bleeding and Transfusion
Spontaneous (nonintracranial) bleeding requiring hos-
pitalization or transfusion in the past 6 months (or at 
any time if recurrent) is considered a major ARC-HBR 
criterion, and a first spontaneous (nonintracranial) 
bleed requiring hospitalization or transfusion >6 and 
<12 months before PCI is considered a minor ARC-HBR 
criterion (Table 3).
Information on the risk of subsequent bleeding in 
patients with a prior bleeding event who undergo PCI 
is scarce. Nonetheless, in the PRECISE-DAPT score, prior 
spontaneous bleeding at any time was found to be an 
important predictor of future bleeding and, in isola-
tion, places patients in the highest quartile for bleeding 
risk.32 In patients (n=320) presenting with peptic ulcer 
bleeding on aspirin monotherapy randomized to treat-
ment with clopidogrel versus aspirin plus esomeprazole 
after confirmed ulcer healing, respective 1-year rates of 
recurrent ulcer bleeding (defined in the Appendix in the 
online-only Data Supplement) were 8.6% versus 0.7% 
(difference, 7.9% [95% CI, 3.4–12.4]; P=0.001).68 In 
another randomized trial in patients (n=153) with acute 
peptic ulcer bleeding on aspirin monotherapy, recurrent 
ulcer bleeding (defined in the Appendix in the online-
only Data Supplement) at 30 days occurred in 10.3% 
versus 5.4% of patients allocated to aspirin plus panto-
prazole versus aspirin discontinuation (HR, 1.9 [95% CI, 
0.6–6.0]; P=0.25).69
Data on the association between previous blood 
transfusion and subsequent bleeding risk in patients 
undergoing PCI are scarce. In 1 randomized trial of 
transfusion strategies in patients without PCI with 
acute upper gastrointestinal bleeding, patients (n=921) 
were assigned to a restrictive (maintain hemoglobin >7 
g/dL) or liberal (maintain hemoglobin >9 g/dL) transfu-
sion strategy. The rate of further in-hospital bleeding 
(defined in the Appendix in the online-only Data Sup-
plement) was significantly lower in patients allocated 
to the restrictive strategy (10% versus 16%; adjusted 
HR, 0.68 [95% CI, 0.47–0.98]; P=0.03).70 The highest 
rates of recurrent bleeding occurred in the setting of 
acute blood transfusion, suggesting that the timing 
of  transfusion appears to an important determinant 
of bleeding risk. Bleeding rates at 1 year were not re-
ported.
Thrombocytopenia
Moderate or severe baseline thrombocytopenia (plate-
let count <100×109/L) is considered a major ARC-HBR 
criterion (Table 3).
Baseline thrombocytopenia refers to thrombocyto-
penia that is present before PCI. This is distinct from 
acquired thrombocytopenia after PCI, which results 
from a postprocedural decline in platelet count in a 
patient without baseline thrombocytopenia. Throm-
bocytopenia is classified as mild (100–149×109/L), 
moderate (50–99×109/L), or severe (<50×109/L).71 The 
reported prevalence of baseline thrombocytopenia in 
patients undergoing PCI is ≈2.5% in the United States 
and 1.5% in Japan.72,73 Patients with thrombocytopenia 
are underrepresented in randomized trials of DES and 
DAPT, and those who are enrolled generally have no 
more than mild thrombocytopenia because a platelet 
count of <100×109/L is a common exclusion criterion.
Thrombocytopenia is a risk factor for both bleeding 
and ischemic complications. In an analysis from the US 
Nationwide Inpatient Sample (NIS) database, 32 565 
patients with chronic thrombocytopenia at the time 
of PCI were propensity-matched with patients with-
out thrombocytopenia.72 The risks of in-hospital post-
procedural bleeding, defined by International Classifi-
cation of Diseases codes for in-hospital complications 
(10.9% versus 4.9%; odds ratio [OR], 2.40 [95% CI, 
2.05–2.72]; P<0.0001), and mortality (6.5% versus 
2.9%; OR, 2.30 [95% CI, 1.90–2.70]; P<0.0001) were 
significantly higher in patients with thrombocytope-
nia.72 A post hoc analysis of patients with ST-segment–
elevation myocardial infarction treated with PCI in the 
HORIZONS-AMI trial (Harmonizing Outcomes With Re-
vascularization and Stents in Acute Myocardial Infarc-
tion; n=3476) showed a higher rate of 30-day ACUITY 
(Acute Catheterization and Urgent Intervention Triage 
Strategy)-HORIZONS major bleeding (defined in the Ap-
pendix in the online-only Data Supplement) in 146 pa-
tients with baseline mild thrombocytopenia compared 
with those without thrombocytopenia (15.4% versus 
9.1%; P=0.01).74
Bleeding risk appears to be proportional to the degree 
of thrombocytopenia. A pooled analysis of 3 Japanese 
studies including patients undergoing PCI (n=19 353) 
showed increased rates of GUSTO (Global Utilization 
of Streptokinase and Tissue Plasminogen Activator for 
Occluded Coronary Arteries) moderate/severe bleed-
ing (defined in the Appendix in the online-only Data 
Supplement) at 3 years in patients with baseline mild 
thrombocytopenia (9.9% versus 6.9%; adjusted HR, 
1.20 [95% CI, 1.03–1.40]; P=0.02) and moderate/se-
vere thrombocytopenia (23.1% versus 6.9%; adjusted 
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HR, 2.35 [95% CI, 1.80–3.08]; P<0.001) compared 
with patients without thrombocytopenia.73
Chronic Bleeding Diatheses
The presence of a clinically significant chronic bleed-
ing diathesis is considered a major ARC-HBR criterion 
(Table 3).
Chronic bleeding diatheses include inherited or 
acquired conditions known to be associated with in-
creased bleeding risk such as platelet dysfunction, von 
Willebrand disease (prevalence of 1%–2% in the gen-
eral population), inherited or acquired clotting factor 
deficiencies (including factors VII, VIII [hemophilia A], IX 
[hemophilia B], and XI), or acquired antibodies to clot-
ting factors, among others.75–77 For the purpose of the 
current HBR definition, thrombocytopenia is discussed 
separately.
Data on bleeding rates after PCI in patients with 
bleeding diatheses are scarce because such patients are 
generally excluded from DES and DAPT trials. In ZEUS-
HBR, hematologic disorders or any known coagulop-
athy-associated bleeding diathesis (including prior or 
current thrombocytopenia, defined as platelet count 
<100×109/L) was a criterion conferring HBR status in 
95 patients (11.5%).5
Among 796 patients with von Willebrand disease 
followed up for 1 year, 75 (9.4%) required clotting fac-
tor replacement therapy for 232 bleeding events.75 In a 
series of 54 patients with hemophilia A or B undergo-
ing coronary angiography or PCI, major periprocedural 
bleeding occurred in 3 patients (6%), and 11 patients 
(20%) had a bleeding event (predominantly minor) 
within 1 year.78 The most important and reliable predic-
tor of bleeding in patients with bleeding diatheses is 
a personal history of bleeding, which may be assessed 
with a bleeding questionnaire.79 However, given the 
lack of data and the low prevalence of such conditions 
in patients undergoing PCI, attempting to weight the 
differential bleeding risks with different bleeding dia-
theses and their levels of severity is beyond the scope 
of the current definition.
Cirrhosis With Portal Hypertension
The presence of cirrhosis with portal hypertension is 
considered a major ARC-HBR criterion (Table 3).
The reported prevalence of cirrhosis in patients un-
dergoing PCI in the United States is 1.2%.80 The bleed-
ing risk in chronic liver disease may be related to im-
paired hemostasis (resulting from coagulation factor 
deficiency, thrombocytopenia, platelet dysfunction, or 
increased fibrinolysis)81 or to esophageal varices in the 
presence of portal hypertension. Bleeding complica-
tions on antithrombotic therapy in such patients are 
potentially catastrophic.82
Patients with severe liver disease are generally ex-
cluded from DES and DAPT trials. In the LEADERS FREE 
trial, although severe chronic liver disease was an inclu-
sion criterion for HBR, <1% of enrolled patients fulfilled 
this criterion.4 The finding of obstructive CAD during 
transplantation workup in patients with end-stage liver 
disease is an increasingly common scenario. A single-
center study of patients (n=1221) who underwent or-
thotopic liver transplantation over a 10-year period in 
the United States reported that 38.6% of patients un-
derwent coronary angiography and 4.7% underwent 
PCI before transplantation, with rates of both increas-
ing over time.83
Data from the NIS registry (n=4 376 950) showed 
that liver disease was an independent predictor of in-
hospital gastrointestinal bleeding in patients undergo-
ing PCI (OR, 2.59 [95% CI, 2.22–3.02]; P<0.001).84 In 
another retrospective study of PCI procedures (n=1 051 
252) in the NIS, 26.0% of patients with cirrhosis had 
a coagulopathy at baseline, 20.5% had anemia, and 
3.9% had a hematologic or oncological malignancy.80 
The in-hospital mortality rate over the study period 
(3.6%) was higher compared with historical studies 
of the NIS database (0.5%–1.1%), and the most com-
mon postprocedural complications were hemorrhage 
(6.6% of patients) and the need for transfusion (11.3% 
of patients). In a retrospective study of patients with 
cirrhosis and CAD (n=148) treated by either coronary 
stenting with DAPT or medical therapy with aspirin 
monotherapy, the rate of gastrointestinal bleeding at 1 
year was 22% versus 5%, respectively (P=0.003).85 An 
observational study of patients with chronic hepatitis 
B virus (n=1674) showed significantly higher bleeding 
rates (defined as International Society on Thrombosis 
and Haemostasis major bleeding or clinically relevant 
nonmajor bleeding)86,87 in patients taking antiplatelet 
therapy compared with those without antiplatelet ther-
apy (9.5% versus 1.8%; HR, 3.28 [95% CI, 1.98–5.42]; 
P< 0.001).88 Although Child-Pugh and Mayo End-Stage 
Liver Disease criteria are used as exclusion criteria in 
some DES and DAPT trials, such scores were validated 
for predicting mortality in end-stage liver disease but 
not for predicting bleeding risk.89–91
Cancer
Active malignancy (excluding nonmelanoma skin can-
cer) is considered a major ARC-HBR criterion (Table 3). 
Active malignancy is defined as diagnosis within the 
previous 12 months or ongoing active cancer treatment 
(surgery, radiotherapy, chemotherapy, or immunothera-
py). Cancer that is considered to be in complete remis-
sion or requires only maintenance therapy (eg, tamoxi-
fen for breast cancer) is not considered active.
The prevalence of current or previous cancer in pa-
tients undergoing PCI in the US NIS database increased 
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from 6.3% in 2004 to 9.5% in 2014.92 Of 6 571 034 
patients undergoing PCI, 1.8% had a current can-
cer diagnosis and 5.8% had previous cancer. Current 
cancer was associated with higher rates of in-hospital 
bleeding (defined by International Classification of 
Diseases, Ninth Revision, Clinical Modification codes, 
shown in the Appendix in the online-only Data Supple-
ment) compared with previous cancer and no cancer 
history (9.7% versus 4.2% versus 3.1%; OR [current 
versus no cancer], 1.92 [95% CI, 1.82–2.04] and OR 
[historical versus no cancer], 1.08 [95% CI, 1.03–1.13]) 
and ranged between 4.9% and 21.2% according to 
the type, site, and spread of the malignancy.92 Bleeding 
in cancer patients may be caused by local invasion, by 
a secondary systemic process, or by cancer treatment 
(Table VI in the online-only Data Supplement).
The LEADERS FREE trial included 239 patients (9.7%) 
with nonskin cancer diagnosed or treated within 3 years 
before the index PCI,4 with 1-year BARC 3 to 5 bleed-
ing in 9.6%. In an observational study of patients ≥65 
years of age undergoing PCI (n=22 798), late bleeding 
(defined as hospitalization for bleeding ≤1 year after 
discharge) was reported in 5.0% of patients with a his-
tory of cancer, which was an independent predictor of 
late bleeding (HR, 1.80 [95% CI, 1.09–2.96]; P=0.02).93
In the TRILOGY ACS trial (Targeted Platelet Inhibition 
to Clarify the Optimal Strategy to Medically Manage 
Acute Coronary Syndromes; n=9240), cancer incidence 
and outcomes were prospectively assessed among 
patients treated with DAPT (including clopidogrel or 
prasugrel) after ACS.94 A new diagnosis of cancer was 
made in 170 patients (1.8%), of whom 53.5% perma-
nently discontinued DAPT and 59% required surgery or 
chemotherapy. GUSTO severe/life-threatening, or mod-
erate bleeding occurred substantially more frequently 
among those with cancer versus those without (11.2% 
versus 1.5%).
Previous Ischemic Stroke or ICH
The presence of a brain arteriovenous malformation 
(bAVM), previous ICH at any time, and moderate or 
severe ischemic stroke (National Institutes of Health 
Stroke Scale score ≥5 on presentation) within 6 months 
before PCI are all considered major ARC-HBR criteria. 
Ischemic stroke at any time not meeting the major crite-
rion is considered a minor ARC-HBR criterion (Table 3).
In the SCAAR Registry (Swedish Coronary Angi-
ography and Angioplasty Registry), 5% to 6% of pa-
tients undergoing PCI reported a prior stroke.95 In the 
NCDR (National Cardiovascular Data Registry) Cath-PCI, 
≈12% of enrolled patients had a history of cerebrovas-
cular disease (defined as prior stroke or carotid steno-
sis).96 Pivotal DES trials, however, excluded patients with 
a prior stroke within 6 months of enrollment (Table I 
in the online-only Data Supplement). In trials of DES 
in patients perceived to be at increased bleeding risk, 
the prevalence of prior stroke was low, and bleeding 
rates for this subgroup were not reported. In LEADERS 
FREE, 1.6% of patients had ischemic stroke within the 
prior 12 months, and 1.3% had prior ICH.4 In ZEUS-
HBR, prior stroke or transient ischemic attack (TIA) was 
reported in 8% of patients.5 In the SENIOR trial, ≈8% of 
the enrolled population had previous ischemic stroke; 
prior ICH was an exclusion criterion.6
Trials of DAPT after ACS have also excluded patients 
with prior ICH but not prior ischemic stroke/TIA.97–99 In the 
TRITON (Trial to Assess Improvement in Therapeutic Out-
comes by Optimizing Platelet Inhibition With Prasugrel)–
TIMI 38 trial, patients with prior TIA or stroke (>3 months 
before inclusion) who received aspirin and prasugrel had 
higher rates of ischemic and hemorrhagic stroke at 15 
months compared with patients without prior TIA/stroke 
(any stroke occurred in 6.5% [2.3% ICH] and 0.9% 
[0.2% ICH], respectively), resulting in a contraindication 
for prasugrel use in such patients.99 In contrast, in patients 
treated with aspirin and clopidogrel, rates of subsequent 
stroke did not significantly differ between patients with 
and those without prior TIA/stroke (1.2% [0% ICH] and 
1.0% [0.3% ICH], respectively). In the PLATO trial (Plate-
let Inhibition and Patient Outcomes; n=18 624), patients 
with prior TIA/stroke (n=1152, 6.2%) treated with DAPT 
(including ticagrelor or clopidogrel) after PCI had signifi-
cantly higher 1-year rates of ICH compared with those 
without prior stroke or TIA (0.8% versus 0.2%; unad-
justed HR, 3.95 [95% CI, 1.82–8.55]; P=0.0005), with 
no significant difference in ICH rates between treatment 
groups (0.9% for ticagrelor versus 0.7% for clopidogrel; 
HR, 1.00 [95% CI, 0.25–3.99]).100 In the TRA-2P [Trial 
to Assess the Effects of Vorapaxar (SCH 530348; MK-
5348) in Preventing Heart Attack and Stroke in Patients 
With Atherosclerosis]–TIMI-50 trial (n=26 449), patients 
with prior stroke 2 weeks to 1 year before enrollment 
(n=5746 [21.7%]) had a significantly higher rate of ICH 
at 3 years with vorapaxar compared with placebo added 
to standard antiplatelet therapy (2.4% versus 0.9%; HR, 
2.55 [95% CI, 1.52–4.28]; P<0.001).101 The rates of ICH 
in patients without prior stroke were markedly lower in 
both treatment groups (0.6% [vorapaxar arm] and 0.4% 
[placebo arm]; HR, 1.55 [95% CI, 1.00–2.41]; P=0.049).
Rates of non-ICH bleeding do not appear to differ 
significantly between patients undergoing PCI with 
and without previous stroke. In PRECISE-DAPT, patients 
with and without prior stroke had similar rates of TIMI 
major/minor bleeding (HR, 1.16 [95% CI, 0.54–2.48]; 
P=0.70).32 In PARIS, rates of BARC 3 or 5 bleeding in 
patients with and without previous stroke were also 
similar (4.1% and 3.5%, respectively; P=0.66).38
Six major randomized trials have investigated potent 
antiplatelet therapy for secondary stroke prevention 
(Table 5).102–107 Three trials enrolled patients with acute 
minor stroke or TIA (<12–24 hours; National  Institutes 
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Table 5. Major Randomized Trials of Antiplatelet Therapy in Recent or Acute Ischemic Stroke or TIA
Trial (Year of 
Publication)
Patients, 
n Indication
Experimental 
Arm
Control
Arm
Duration 
of 
Treatment 
and 
Follow-Up Ischemic (Efficacy) Outcomes
Bleeding (Safety) 
Outcomes
Trials of antiplatelet therapy in recent stroke or TIA
  MATCH 
(2004)105
7599 Recent ischemic 
stroke or TIA (<3 
mo)+≥1 additional 
vascular risk factor
(all patients were 
on clopidogrel 
monotherapy at 
baseline)
Aspirin 75 mg 
once daily plus 
clopidogrel 75 
mg once daily
Clopidogrel 
75 mg 
once daily
18 mo Composite of ischemic stroke, MI, 
readmission, or vascular death: 15.7% vs 
16.7% (absolute risk
reduction, 1% [95% CI, –0.6 to 2.7]; 
P=0.244)*
Ischemic stroke: 8% vs 9% (absolute risk
reduction, 0.62% [95% CI, –0.6 to 1.9]; 
P=0.353)
Life-threatening bleeding: 
2.6% vs 1.3% (absolute 
risk increase, 1.3% [95% 
CI, 0.6 to 1.9]; P<0.0001)
Primary ICH: 1% vs <1% 
(absolute risk increase, 
0.40 [95% CI, 0.04 to 
0.76]; P=0.029)
  PRoFESS 
(2008)106
20 332 Recent ischemic 
stroke (<90 d before 
randomization)+age 
≥50 y or
ischemic stroke 
90–120 d before 
randomization+2 
additional vascular 
risk factors
Aspirin 25 mg 
plus extended-
release 
dipyridamole 
200 mg twice 
daily
Clopidogrel 
75 mg 
once daily‡
30 mo Stroke (any): 9.0% vs 8.8% (HR, 1.01 
[95% CI, 0.92 to 1.11])*
Ischemic stroke: 7.7% vs 7.9% (HR, 
0.97 [95% CI, 0.88 to 1.07]; P=NS)
Composite of stroke, MI, or death 
from vascular causes: 13.1% in both 
groups (HR, 0.99 [95% CI, 0.92 to 
1.07])
Major bleeding: 4.1% vs 
3.6% (HR, 1.15 [95% CI, 
1.00 to 1.32])
ICH: 1.4% vs 1.0% (HR, 
1.42 [95% CI, 1.11 to 
1.83]; P=0.006)
  SPS3 
(2012)107
3020 Recent
symptomatic 
lacunar infarct 
(≤180 d before 
randomization)
Aspirin 325 
mg once 
daily plus 
clopidogrel 75 
mg once daily
Aspirin 325 
mg once 
daily
Mean, 3.4 
y (range, 
0–8.2 y)
Stroke (any): 2.5%/y vs 2.7%/y (HR, 
0.92 [95% CI, 0.72 to 1.16]; P=0.48)*
Ischemic stroke: 2.0%/y vs 2.4%/y (HR, 
0.82 [95% CI, 0.63 to 1.09]; P=0.13)
Death: 2.1% vs 1.4% (HR, 1.52 [95% 
CI, 1.14 to 2.04]; P=0.004)
Major bleeding: 2.1%/y vs 
1.1%/y (HR, 1.97 [95% CI, 
1.41 to 2.71]; P<0.001)
ICH: 0.42%/y vs 0.28%/y 
(HR, 1.52 [95% CI, 0.79 to 
2.93]; P=0.21)
Trials of antiplatelet therapy in acute stroke or TIA
  CHANCE 
(2014)102
5170 Acute (≤24 h) minor 
ischemic stroke 
(NIHSS score ≤3) or 
high-risk TIA†
Clopidogrel 
75 mg once 
daily+aspirin 
75 mg once 
daily (for the 
first 21 d)
Aspirin 75 
mg once 
daily
90 d Stroke (any): 8.2% vs 11.7% (HR, 0.68 
[95% CI, 0.58 to 0.82]; P<0.001)*
Ischemic stroke: 7.9% vs 11.4% (HR, 
0.67 [95% CI, 0.56 to 0.81]; P<0.001)
Composite of stroke, MI, or cardiac 
death: 8.4% vs 11.9% (HR, 0.68 [95% 
CI, 0.59 to 0.82]; P<0.001)
Moderate or severe 
bleeding (GUSTO): 0.3% 
in both arms (P=0.73)
Hemorrhagic stroke: 
0.3% in both arms (HR, 
1.01 [95% CI, 0.38 to 
2.70]; P=0.98)
  SOCRATES 
(2016)103
13 199 Acute (≤24 h) 
nonsevere ischemic 
stroke
(NIHSS score ≤5) 
or high-risk TIA† 
or symptomatic 
intracranial or
extracranial arterial 
stenosis
Ticagrelor 90 
mg twice daily
Aspirin 100 
mg once 
daily
90 d Stroke, MI, or death: 6.8% vs 7.5% 
(HR, 0.89 [95% CI, 0.78 to 1.01]; 
P=0.07)*
Ischemic stroke: 5.9 vs 6.6% (HR, 
0.87 [95% CI, 0.76 to 1.00]; P=0.05)
Major bleeding (PLATO): 
0.5% vs 0.6% (HR, 0.83 
[95% CI, 0.52 to 1.34]; 
P=0.45)
ICH: 0.2% vs 0.3% (HR, 
0.68 [95% CI, 0.33 to 
1.41; P=0.30)
  POINT 
(2018)104
4881 Acute (≤12h) minor 
ischemic stroke 
(NIHSS score ≤3) or 
high-risk TIA†
Aspirin 
50–325 mg 
once daily plus 
clopidogrel 75 
mg once daily
Aspirin 
50–325 mg 
once daily
90 d Composite of ischemic stroke, MI, 
or death resulting from an ischemic 
vascular event: 5.0% vs 6.5% (HR, 0.75
[95% CI, 0.59 to 0.95]; P=0.02)*
Ischemic stroke: 4.6% vs 6.3% (HR, 
0.72 [95% CI, 0.56–0.92]; P=0.01)
Major bleeding: 0.9% vs 
0.4% (HR, 2.32 [95% CI 
1.10 to 4.87]; P=0.02)
Hemorrhagic stroke: 0.2% 
vs 0.1% (HR, 1.68 [95% 
CI, 0.40 to 7.03]; P=0.47)
Bleeding definitions are shown in the Appendix in the online-only Data Supplement. 
CHANCE indicates Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events; GUSTO, Global Utilization of Streptokinase and Tissue 
Plasminogen Activator for Occluded Coronary Arteries; HR, hazard ratio; ICH, intracranial hemorrhage; MATCH, Management of Atherothrombosis With Clopidogrel 
in High-Risk Patients; MI, myocardial infarction; NIHSS, National Institutes of Health Stroke Scale; NS, not significant; PLATO, Study of Platelet Inhibition and 
Patient Outcomes; POINT, Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke; PRoFESS, Prevention Regimen for Effectively Avoiding Second Strokes; 
SOCRATES, Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes; SPS3, Secondary Prevention of Small Subcortical 
Strokes; and TIA, transient ischemic attack.
*Primary outcome.
†High-risk TIA in CHANCE, SOCRATES, and POINT was defined as TIA with a moderate to high risk of stroke recurrence (defined as ABCD2 stroke risk score of ≥4; 
ABCD score assesses the risk of stroke based on age, blood pressure, clinical features, duration of TIA, and presence or absence of diabetes mellitus; scores range 
from 0–7, with higher scores indicating greater short-term risk of stroke).
‡Protocol amendment in PRoFESS: because of a concern with an increased risk of bleeding, after 2027 patients had been enrolled, the clopidogrel plus aspirin 
arm was modified, and the next 18 305 patients were randomized to either clopidogrel alone or the unmodified combination of low-dose aspirin and dipyridamole.
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of Health Stroke Scale score <3–5) and showed no sig-
nificant difference in ICH rates between patients treat-
ed with either DAPT or ticagrelor and those treated 
with aspirin monotherapy for 90 days.102–104 MATCH 
(Management of Atherothrombosis With Clopidogrel 
in High-Risk Patients) and PRoFESS (Prevention Regimen 
for Effectively Avoiding Second Strokes) enrolled pa-
tients with recent stroke (≤90–120 days). In both trials, 
overall rates of bleeding and primary ICH were higher 
with DAPT compared with clopidogrel monotherapy, 
without a significant reduction in ischemic events.105,106 
The SPS3 trial (Secondary Prevention of Small Subcor-
tical Strokes) patients also showed significantly higher 
major bleeding rates and no significant reduction in re-
current stroke with DAPT compared with aspirin mono-
therapy in patients with recent symptomatic lacunar 
infarcts (≤180 days).107 However, in contrast to MATCH 
and PRoFESS, rates of ICH were comparable between 
treatment groups, but mortality rates were significantly 
higher with DAPT. In line with these findings, American 
Stroke Association/American Heart Association guide-
lines recommend (Class IIa, Level of Evidence B-R) that 
DAPT (aspirin and clopidogrel) initiated within 24 hours 
can be beneficial for early secondary prevention for a 
period of up to 90 days,108 but it is not recommended 
(Class III, Level of Evidence A) for routine long-term sec-
ondary prevention after minor stroke or TIA.109
There is a lack of prospective data on DAPT and 
bleeding risk in patients with large strokes, prior ICH, 
and bAVMs. Patients with bAVMs have a high long-
term risk of ICH.110 In a patient-level meta-analysis of 
2525 patients with bAVM, the annual risk of first and 
recurrent ICH was 1.3% (95% CI, 1.0–1.7) and 4.8% 
(95% CI, 3.9–5.9), respectively.111 In a randomized 
study of unruptured bAVMs (n=223), the annual first 
ICH rate without interventional therapy was 2.0%.112 
The incremental risk of ICH in patients with bAVM tak-
ing antiplatelet therapy is not known.
Planned Major Noncardiac Surgery  
After PCI
Planned nondeferrable major surgery on DAPT after PCI 
is considered a major ARC-HBR criterion (Table 3).
After PCI, up to 17% of patients undergo an invasive 
diagnostic or therapeutic procedure within 1 year.113,114 
The increased risk of bleeding in a patient on antiplate-
let therapy undergoing major surgery must be balanced 
against the potential risks of discontinuing DAPT in the 
potentially prothrombotic perioperative setting.113,114 
Important considerations include (1) the temporal re-
lationship between PCI and surgery, (2) whether the 
surgery is deferrable, (3) the anticipated bleeding risk 
specific to the surgical procedure, and (4) the antici-
pated thrombotic risk as defined by patient, lesion, and 
procedural characteristics.
In the POISE-2 trial (Perioperative Ischemic Evalu-
ation 2; n=10 010), 30-day major bleeding rates (de-
fined in the Appendix in the online-only Data Sup-
plement) after noncardiac surgery were higher with 
aspirin compared with placebo (4.6% versus 3.8%; 
HR, 1.23 [95% CI, 1.01–1.49]; P=0.04).115 Although 
clinical practice guidelines provide recommendations 
on perioperative management of antithrombotic ther-
apy, they do not define the perioperative bleeding risk 
of different surgical procedures.116,117 To this end, a 
number of national multidisciplinary expert consensus 
documents have been published in an effort to stan-
dardize perioperative management of antithrombotic 
therapy based on balancing the predicted patient-
specific ischemic risk with the anticipated procedure-
specific bleeding risk.118–120
In summary, DAPT at the time of or shortly after sur-
gery increases bleeding risk. Most elective surgery can 
be deferred beyond the proposed DAPT duration, and 
elective PCI is rarely necessary before elective major sur-
gery. For urgent or nondeferrable surgery, the risk of 
stent thrombosis is much higher during the first month 
after PCI compared with subsequent months..121,122
PCI After Recent Major Surgery  
or Trauma
Major surgery or major trauma within 30 days before 
PCI is considered a major ARC-HBR criterion (Table 3).
The reported incidence of perioperative myocardial 
infarction after major noncardiac surgery is as high 
as 10%, depending on both patient and procedural 
characteristics.123 No data are available on bleeding 
rates when urgent PCI is required after recent ma-
jor surgery or trauma. The bleeding risk of different 
types of surgery (including trauma surgery) has been 
reviewed recently.118
Long-Term Oral NSAID or Steroid Use
Long-term steroid or oral NSAID use (defined as planned 
daily intake for ≥4 d/wk) is considered a minor ARC-
HBR criterion (Table 3).
NSAIDs represent the most widely used class of 
medications worldwide.124,125 Both oral NSAIDs and 
steroids are associated with increased gastrointestinal 
bleeding risk, which is dose-dependent and increases 
with long-term use.126,127 There is a paucity of data on 
bleeding risk in patients with long-term oral NSAID 
or steroid use after PCI because of underrepresenta-
tion or underreporting in randomized trials. Although 
long-term NSAID or steroid use was an inclusion cri-
terion in both LEADERS FREE and ZEUS-HBR, this cri-
terion was met in only 72 patients (2.8%) and 25 pa-
tients (3%), respectively.4,5 Moreover, their bleeding 
rates were not reported.
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The risk of upper gastrointestinal bleeding is higher 
with NSAID monotherapy compared with aspirin mono-
therapy, and concomitant use of NSAIDs and aspirin 
substantially further increases the risk.37,128 In the CON-
CERN trial (n=514), patients with arthritis presenting 
with upper gastrointestinal bleeding on NSAIDs with a 
requirement for low-dose aspirin were randomized to 
celecoxib or naproxen (plus aspirin and esomeprazole) 
after confirmed ulcer healing. Recurrent upper gastroin-
testinal bleeding (defined in the Appendix in the online-
only Data Supplement) rates were 5.6% and 12.3% at 
18 months, respectively (HR, 0.44 [95% CI, 0.23–0.82]; 
P=0.008).129 In the CLASS study (Celecoxib Long-Term 
Arthritis Safety Study; n=8059), patients with arthritis 
were randomized to celecoxib or either ibuprofen or 
diclofenac. In the subgroup of patients taking aspirin, 
the rates of symptomatic upper gastrointestinal ulcers 
or complications (bleeding, perforation, and obstruc-
tion) at 6 months were 4.7% and 6.0%, respectively 
(P=0.49).130
SPECIAL CONSIDERATIONS
Frailty
Frailty was not included as a criterion because of the 
paucity of data demonstrating a causative role in bleed-
ing in patients undergoing PCI and the lack of a con-
sensus on how frailty is best assessed.131 Bleeding risk 
may be increased in the setting of frailty as a result of 
more frequent falls, the inability to ambulate without 
assistance, or postural hypotension. When frailty was 
evaluated with a functional impairment score in the 
ACTION Registry (Acute Coronary Treatment and Inter-
vention Outcomes Network), it was found to correlate 
with an increased risk of major in-hospital bleeding 
(defined in the Appendix in the online-only Data Sup-
plement) in 112 000 elderly patients presenting with 
acute myocardial infarction undergoing cardiac cath-
eterization. Major bleeding occurred in 6.4%, 10.3%, 
and 13.6% of patients with no, mild, and moderate 
to severe frailty, respectively (mild frailty–adjusted HR, 
1.33 [95% CI, 1.23–1.44]; moderate to severe frailty–
adjusted HR, 1.40 [95% CI, 1.24–1.58] compared with 
the group without frailty).132 The inclusion of advanced 
age and coexisting ARC-HBR criteria may account, to 
some degree, for frailty. Further studies on the impact 
of frailty on bleeding risk are encouraged.
Ethnicity
The role of ethnicity in post-PCI bleeding risk has not 
been fully elucidated. Nonetheless, lower doses of 
several antithrombotic regimens are recommended in 
Asian patients compared with patients in Europe or the 
United States because of greater bleeding  concerns in 
Asians.133,134 Bleeding models developed in Western 
populations tend to underestimate bleeding risk in 
Asian populations.135 In a patient-level meta-analysis, 
which pooled 7 randomized trials (n=16 518; 8605 East 
Asians, 7913 non-Asians), major bleeding occurred 
more frequently in East Asians (0.6% versus 0.3%; 
P=0.001), whereas major adverse cardiac events oc-
curred more frequently in non–East Asians (0.8% versus 
1.8%; P<0.001),136 suggesting a differential ischemia/
bleeding tradeoff in East Asians and non–East Asians. 
Further research is needed in this field.
Acute Coronary Syndromes
Compared with stable patients with CAD, patients 
with ACS are at increased thrombotic risk, warranting 
treatment with more potent, longer-duration antiplate-
let therapy. However, such an approach inevitably in-
creases bleeding risk. In a meta-analysis of 3 random-
ized trials of patients with ACS (n=17 393) undergoing 
PCI with bivalirudin or heparin plus a glycoprotein IIb/
IIIa inhibitor, the rate of TIMI major/minor bleeding was 
5.3% at 30 days.137 In selected patients with ST-seg-
ment–elevation myocardial infarction at low bleeding 
risk, respective 1-year rates of non–coronary artery by-
pass graft TIMI major/minor bleeding were 4.0% and 
3.5% with ticagrelor and clopidogrel in the PLATO trial 
and 5.1% and 4.7% with prasugrel and clopidogrel in 
the TRITON-TIMI 38 trial.138,139 Other trials of patients 
with ACS with more stringent exclusion criteria have 
reported 2-year BARC 3 to 5 bleeding rates as low as 
0.5% to 0.8%.34 Given that the increased bleeding risk 
in patients with ACS is attributable to the more aggres-
sive antiplatelet therapy rather than the ACS per se, the 
consensus was not to consider ACS an HBR criterion.
DAPT Nonadherence
DAPT nonadherence after PCI is well described. In the 
PARIS study, at a time when guidelines recommended 
≥12 months of DAPT for all patients after stenting, 
the rate of DAPT discontinuation was 2.6%, 11.8%, 
and 19.9% at 30 days, 6 months, and 12 months, 
respectively.140 In contrast, in trials investigating short 
DAPT regimens, nonadherence to recommended DAPT 
discontinuation may occur. For example, in the LEAD-
ERS FREE trial, despite a recommended 1-month DAPT 
duration, ≈9% remained on DAPT after 1 month.4 In 
the SENIOR trial, 20% of patients remained on DAPT 
at 12 months, well beyond the recommended 1 to 6 
months.6 In the ZEUS trial, although all patients at HBR 
were prescribed DAPT for 30 days, 38% remained on 
DAPT at 2 months and 25% at 6 months.5,35 Although 
DAPT nonadherence may increase the risk of throm-
botic complications, nonadherence with recommended 
discontinuation may increase bleeding complications.
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REGULATORY CONSIDERATIONS
Studies of patients at HBR have intrinsic public health 
value and support the mission of regulatory bodies. 
Consensus definitions are necessary to improve the 
efficiency and predictability of study design and qual-
ity and can assist regulatory decision-making for safe 
and effective drugs and devices for patients at HBR in 
a timely fashion. Sex, nationality, and ethnic differences 
in bleeding risk may also be important considerations in 
trial design and the interpretation of study outcomes. 
This article reflects the consensus views of the ARC-HBR 
consortium and does not necessarily represent the prac-
tices, policies, requirements, or recommendations of 
the US Food and Drug Administration or the Japanese 
Pharmaceuticals and Medical Devices Agency. Further-
more, the recommendations in this document do not 
represent a regulatory requirement from either agency. 
Although regulators consider it acceptable to propose 
and justify alternative definitions and HBR criteria, they 
encourage investigators to discuss any proposed trial-
specific definitions of HBR prospectively with the rel-
evant regulatory bodies before study initiation.
LIMITATIONS
A number of important limitations of the proposed def-
inition must be acknowledged. First, the chosen cutoff 
values for 1-year BARC 3 or 5 bleeding (4%) and ICH 
(1%) are arbitrary, according to the expert opinion of 
this group. Second, data on rates of BARC 3 or 5 bleed-
ing or ICH at 1 year were not available for a number of 
criteria, in which case justification is based on consen-
sus decision alone. Third, although the relationship be-
tween many criteria and bleeding is continuous, binary 
criteria have been used to simplify the definition and to 
facilitate its use in trial enrollment. In addition, the dif-
ferential bleeding risks associated with the criteria have 
not been weighted beyond major and minor because of 
a lack of data to support such an approach. Finally, the 
definition has not been validated in an independent pa-
tient data set. To this end, as more data become avail-
able, we anticipate validation and recalibration of this 
initial set of HBR criteria.
CONCLUSIONS
In keeping with previous ARC initiatives, this ARC-
HBR definition addresses an unmet need by providing 
a framework for evaluating treatment options for pa-
tients undergoing PCI at increased bleeding risk. It is ex-
pected that consistent use of the consensus definitions 
will improve our ability to tailor treatment to individual 
patient needs and to stimulate scientific progress, in-
novation, and quality control initiatives. We therefore 
encourage trialists and trial sponsors to consider using 
ARC-HBR definitions in clinical studies with reporting of 
BARC 3 or 5 bleeding rates to allow comprehensive and 
consistent assessment of patients at HBR.
The ARC-HBR group is cognizant that defining 
bleeding risk is the first step toward understanding the 
continuum of clinically meaningful risks and benefits in 
patients at HBR undergoing PCI. Evaluating and man-
aging the risk of major bleeding must always be bal-
anced by the assessment of the thrombotic risk. This 
balance will be addressed in a future phase of the ARC-
HBR initiative.
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